COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 1

Omalizumab en el tratamiento de asma alérgico persistente moderado a severo

INTRODUCCION: Se define al asma alérgico como una enfermedad heterogénea, que generalmente se caracteriza por una inflamación crónica de las vías aéreas. La inmunoglobulina E (IgE) desempeña un papel importante en el desarrollo del asma alérgica, se une a las cé-lulas inflamatorias como mastoc...